AR073078A1 - Construcciones flt (vegf- factor de crecimiento del endotelio vascular) solubles para el tratamiento del cancer. - Google Patents

Construcciones flt (vegf- factor de crecimiento del endotelio vascular) solubles para el tratamiento del cancer.

Info

Publication number
AR073078A1
AR073078A1 ARP090103169A ARP090103169A AR073078A1 AR 073078 A1 AR073078 A1 AR 073078A1 AR P090103169 A ARP090103169 A AR P090103169A AR P090103169 A ARP090103169 A AR P090103169A AR 073078 A1 AR073078 A1 AR 073078A1
Authority
AR
Argentina
Prior art keywords
flt
vegf
domain
endotelium
vascular
Prior art date
Application number
ARP090103169A
Other languages
English (en)
Spanish (es)
Inventor
Rebecca Bagley
Clark Pan
Johanne Kaplan
Beverly Teicher
Jim Stefano
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of AR073078A1 publication Critical patent/AR073078A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
ARP090103169A 2008-08-15 2009-08-18 Construcciones flt (vegf- factor de crecimiento del endotelio vascular) solubles para el tratamiento del cancer. AR073078A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8931108P 2008-08-15 2008-08-15
US9250508P 2008-08-28 2008-08-28

Publications (1)

Publication Number Publication Date
AR073078A1 true AR073078A1 (es) 2010-10-13

Family

ID=41669536

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090103169A AR073078A1 (es) 2008-08-15 2009-08-18 Construcciones flt (vegf- factor de crecimiento del endotelio vascular) solubles para el tratamiento del cancer.

Country Status (2)

Country Link
AR (1) AR073078A1 (fr)
WO (1) WO2010019263A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4944032B2 (ja) 2004-09-13 2012-05-30 ジェンザイム・コーポレーション 多量体構築物
WO2012019128A1 (fr) * 2010-08-06 2012-02-09 Genzyme Corporation Compositions d'antagonistes de vegf et leurs applications
WO2013148117A1 (fr) 2012-03-27 2013-10-03 Ngm Biopharmaceuticals, Inc. Compositions et méthodes d'utilisation pour le traitement de troubles métaboliques
BR112015018104A2 (pt) 2013-01-30 2017-11-21 Ngm Biopharmaceuticals Inc polipeptídeos de gdf15 modificados, seu uso, composições compreendendo os mesmos e recipiente estéril compreendendo as referidas composições
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
BR112017001789A2 (pt) 2014-07-30 2018-07-24 Ngm Biopharmaceuticals, Inc. composições e métodos de uso para tratamento de distúrbios metabólicos
KR20170074852A (ko) * 2014-10-31 2017-06-30 엔지엠 바이오파마슈티컬스, 아이엔씨. 대사 장애를 치료하기 위한 조성물 및 사용 방법
CN117986363A (zh) 2016-03-31 2024-05-07 恩格姆生物制药公司 结合蛋白及其使用方法
KR101685532B1 (ko) * 2016-04-26 2016-12-13 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질
WO2019219048A1 (fr) * 2018-05-18 2019-11-21 北京辅仁瑞辉生物医药研究院有限公司 Conjugué polypeptidique fusionné ayant une durée de demi-vie prolongée
EP3814381A4 (fr) * 2018-06-29 2022-08-10 Gensun Biopharma Inc. Antagonistes trispécifiques

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
AU2002313825A1 (en) * 2001-08-27 2003-03-10 Tanox, Inc. Method for removing endotoxins from protein solutions
JP4944032B2 (ja) * 2004-09-13 2012-05-30 ジェンザイム・コーポレーション 多量体構築物
EP1824988B1 (fr) * 2004-11-12 2017-04-19 Bayer HealthCare LLC Modification du facteur fviii en fonction du site

Also Published As

Publication number Publication date
WO2010019263A3 (fr) 2010-08-12
WO2010019263A2 (fr) 2010-02-18

Similar Documents

Publication Publication Date Title
AR073078A1 (es) Construcciones flt (vegf- factor de crecimiento del endotelio vascular) solubles para el tratamiento del cancer.
CY1119243T1 (el) Φαρμακοτεχνικες μορφες ανταγωνιστη του vegf
CY1122060T1 (el) Συνδυαστικη θεραπευτικη χρηση αντισωματων και ενδογλυκοσιδασεων
GEP20227447B (en) Constructs having sirp-alpha domain or variant thereof
JP2017000143A5 (fr)
CY1117695T1 (el) Υψηλης συγγενειας ανθρωπινα αντισωματα κατα της ανθρωπινης αγγειοποιητινης-2
BR112018068189A2 (pt) proteínas de ligação induzíveis e métodos de uso
SA517390092B1 (ar) مجالات تكرار أنكيرين مصمَّمة ذات نوعية ربط تجاه ألبومين مصل
CY1114244T1 (el) Σκευασματα ανταγωνιστη vegf καταλληλα για ενδοϋαλωδη χορηγηση
CY1118200T1 (el) Πολυπεπτιδια, πολυνουκλεοτιδια και συνθεσεις για χρηση στη θεραπεια λανθανουσας φυματιωσης
CY1116288T1 (el) Tnfsf απλης αλυσου μορια
BR112017007816A2 (pt) composições farmacêuticas compreendendo variantes de peptídeos e métodos de uso das mesmas
DK1615952T3 (da) Fremgangsmåder til behandling af betændelsestilstande med specifikke, til humant angiopoietin-2-bindende midler
PE20091405A1 (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf
RU2014150224A (ru) Сконструированный белок с анкириновым повтором, связывающийся с фактором роста тромбоцитов
TR201815552T4 (tr) Agregasyon ile ilgili hastalıkların tedavisine yönelik iyileştirilmiş nanoantikorlar (TM).
WO2019157366A8 (fr) Domaines variables d'anticorps ciblant le récepteur nkg2d
MX2019003298A (es) Proteinas de union recombinantes y sus usos.
EA202092589A2 (ru) Cxcr2-связывающие полипептиды
BRPI0512286A (pt) proteìnas quiméricas inibidoras da angiogênese e o uso
FI3452507T3 (fi) Tau-immuunihoito
AU2003228962A1 (en) Ferritin fusion proteins for use in vaccines and other applications
DE60032486D1 (de) Prion protein peptide und deren verwendung
PE20140190A1 (es) Moduladores de proteinas notum y metodos de uso
ECSP088299A (es) Modulacion de la expresion del receptor de glucagon

Legal Events

Date Code Title Description
FB Suspension of granting procedure